{"id":306,"date":"2025-01-21T05:05:30","date_gmt":"2025-01-21T05:05:30","guid":{"rendered":"https:\/\/caribiotech.com\/?p=306"},"modified":"2025-01-21T05:05:41","modified_gmt":"2025-01-21T05:05:41","slug":"cbl-y-la-universidad-nacional-evangelica-obtienen-la-aprobacion-de-proyecto-de-fondocyt","status":"publish","type":"post","link":"https:\/\/caribiotech.com\/en\/2025\/01\/21\/cbl-y-la-universidad-nacional-evangelica-obtienen-la-aprobacion-de-proyecto-de-fondocyt\/","title":{"rendered":"CBL and the National Evangelical University obtain approval for FondoCyT project"},"content":{"rendered":"\n

The project \u201cDEVELOPMENT OF A NEW TECHNIQUE THROUGH IMMUNOAFFINITY FOR THE DIAGNOSIS OF NEUROLOGICAL SYNDROMES ASSOCIATED WITH LUNG CANCER\u201d<\/strong>will be developed over a period of 3 years and seeks the research and development of a diagnostic technique for neurological disease syndromes associated with lung cancer, using the ELISA technique (Enzyme-linked immunosorbent assay). The result of the Project aims to demonstrate that the ELISA technique is equal to or more sensitive than radioimmunoassay techniques (RIA: Radio-Immune Assay) by replacing the radioactive isotopes and toxins it uses, with the use of antigen-antibody complexes that are monitored by enzymatic reactions.
<\/p>\n\n\n\n

\"\"<\/figure>\n<\/body>","protected":false},"excerpt":{"rendered":"

El proyecto\u00a0\u201cDESARROLLO DE UNA NUEVA T\u00c9CNICA A TRAV\u00c9S DE LA INMUNOAFINIDAD PARA EL DIAGN\u00d3STICO DE S\u00cdNDROMES NEUROL\u00d3GICOS ASOCIADOS CON EL C\u00c1NCER DE PULM\u00d3N\u201d\u00a0se desarrollar\u00e1 durante un per\u00edodo de 3 a\u00f1os y busca la investigaci\u00f3n y el desarrollo de una t\u00e9cnica de diagn\u00f3stico para los s\u00edndromes de enfermedades neurol\u00f3gicas asociadas con el c\u00e1ncer de pulm\u00f3n, utilizando […]<\/p>\n","protected":false},"author":1,"featured_media":273,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_angie_page":false,"om_disable_all_campaigns":false,"page_builder":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias"],"jetpack_featured_media_url":"https:\/\/caribiotech.com\/wp-content\/uploads\/2025\/01\/CBL-and-Universidad-Nacional-Evangelica-obtain-project-approval-from-FondoCyT-Logos.jpg","_links":{"self":[{"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/posts\/306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/comments?post=306"}],"version-history":[{"count":1,"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/posts\/306\/revisions"}],"predecessor-version":[{"id":308,"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/posts\/306\/revisions\/308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/media\/273"}],"wp:attachment":[{"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/media?parent=306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/categories?post=306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/caribiotech.com\/en\/wp-json\/wp\/v2\/tags?post=306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}